ESHAP regimen
WikiDoc Resources for ESHAP regimen |
Articles |
---|
Most recent articles on ESHAP regimen Most cited articles on ESHAP regimen |
Media |
Powerpoint slides on ESHAP regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on ESHAP regimen at Clinical Trials.gov Trial results on ESHAP regimen Clinical Trials on ESHAP regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on ESHAP regimen NICE Guidance on ESHAP regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on ESHAP regimen Discussion groups on ESHAP regimen Patient Handouts on ESHAP regimen Directions to Hospitals Treating ESHAP regimen Risk calculators and risk factors for ESHAP regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for ESHAP regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:ESHAP Regimen; Etoposide-Solumedrol-High Dose Ara-C, Platinol Regimen
Overview
ESHAP regimen refers to a regimen consisting of etoposide, methylprednisolone (Solumedrol), high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin's and Non-Hodgkin's lymphoma[1][2] and rituximab added for the treatment of
Regimen
EEtoposide
SMethylprednisolone (Solumedrol)
HHigh-dose
ACytarabine (Ara-c)
PCisplatin (Platinol)
Indications
- Relapsed and refractory Hodgkin's and Non-Hodgkin's lymphoma[1][3]
References
- ↑ 1.0 1.1 Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA; et al. (1994). "ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study". J Clin Oncol. 12 (6): 1169–76. PMID 8201379.
- ↑ "NCI Thesaurus".
- ↑ "NCI Thesaurus".